EGFR and adenocarcinoma: In conclusion, the results of the present study indicated that intercalated treatment with chemotherapy and EGFR TKIs does not improve ORR, PFS, and OS compared to chemotherapy alone in patients in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.